WHAT IS CLAIMED IS:

1	1. A composition-comprising a haptenized tumor cell or tumor cell extract				
2	comprising from about 2×10 ⁵ to about 2.5×10 ⁶ tumor cells or cell equivalents per dose, wherein				
3	the tumor cells or cell equivalents are conjugated to a hapten and rendered incapable of growth o				
4	multiplication in vivo.				
1	2. The composition of claim 1, wherein the hapten is selected from the group				
2	consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(5-sulfonic 1-naphthyl) ethylene				
3	diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, arsenic acid benzene				
4	isothiocyanate, sulfanilic acid, arsanilic acid, dinitrobenzene-S-mustard and combinations				
	thereof.				
1	3. The composition of claim 2, in which the hapten is dinitrophenyl.				
1	4. The composition of claim 1, wherein the tumor cell extract comprises tumor cell				
2	membrane components.				
1	5. The composition of claim 1, wherein the tumor cell extract comprises tumor cell				
2	polypeptides.				
1	6. The composition of claim 1, wherein the tumor cells or tumor cell extracts				
2	originate from a tumor selected from the group consisting of melanoma, ovarian cancer, colon				
3	cancer, breast cancer, rectal cancer, lung cancer, kidney cancer, prostate cancer, and leukemia.				
1	7. The composition of claim 6, wherein the tumor is melanoma.				
	O TI				
1	8. The composition of claim 6, wherein the tumor is ovarian cancer.				

	1		9.	The composition of claim 1, wherein the tumor cell or tumor cell extract has been			
	2	rendered incapable of growth by irradiation.					
	1		10.	The composition of claim 1, free of any adjuvant.			
	1		11.	A method for inducing an arti-tumor response in a mammalian patient suffering			
	2	from a	tumor,	which method comprises administering to the patient a composition comprising a			
	3	hapten	ized tur	mor cell or tumor cell extract comprising from about 2×10 ⁵ to about 2.5×10 ⁶ tumor			
	4	cells or cell equivalents per dose, wherein the tumor cells or cell equivalents are conjugated to a					
	5	hapten	i, and re	endered incapable of growth or multiplication in vivo.			
13							
and then then that the	1	V	12.	The method of claim 10, which further comprises administering a first dose of the			
10	2	compo	sition v	vithout any adjuvant.			
ind dim							
سينبذ							
81	1	\	13.	The method of claim 10, wherein the composition is administered prior to a			
3 }	1 2	•		The method of claim 10, wherein the composition is administered prior to a osition comprising an adjuvant and a tumor cell or tumor cell extract, which second			
	•	•	d composition	osition comprising an adjuvant and a tumor cell or tumor cell extract, which second			
3 }	2	second	d composition a) is composition	osition comprising an adjuvant and a tumor cell or tumor cell extract, which second onjugated to a hapten, and			
3 }	2	second	d composition a) is composition	osition comprising an adjuvant and a tumor cell or tumor cell extract, which second			
3 }	2	second	d composition a) is composition b) composition	osition comprising an adjuvant and a tumor cell or tumor cell extract, which second onjugated to a hapten, and stains from about 2×10^5 to about 2.5×10^6 tumor cells or tumor cell equivalents.			
3 }	2	second	a) is consistion b) con	onjugated to a hapten, and attains from about 2×10^5 to about 2.5×10^6 tumor cells or tumor sell equivalents. The method of claim 13, wherein the adjuvant is selected from the group			
3 }	2	second	a) is consistion b) con	osition comprising an adjuvant and a tumor cell or tumor cell extract, which second onjugated to a hapten, and stains from about 2×10^5 to about 2.5×10^6 tumor cells or tumor cell equivalents.			
3 }	2 3 5 5 1 2	second	a) is constitution a) is constitution b) constitution 14.	onjugated to a hapten, and attains from about 2×10^5 to about 2.5×10^6 tumor cells or tumor cell equivalents. The method of claim 13, wherein the adjuvant is selected from the group <i>Bacille Calmette-Guerin</i> , Q-21, and detoxified endotoxin.			
3 }	2 3 5 5 1 2	consis	a) is constitution a) is constitution b) constitution 14. sting of	onjugated to a hapten, and trains from about 2×10^5 to about 2.5×10^6 tumor cells or tumor sell equivalents. The method of claim 13, wherein the adjuvant is selected from the group Bacille Calmette-Guerin, Q-21, and detoxified endotoxin. The method of claim 11, wherein the composition is administered prior to the			
3 }	2 3 5 5 1 2	consis	a) is constitution a) is constitution b) constitution 14. sting of	onjugated to a hapten, and stains from about 2×10^5 to about 2.5×10^6 tumor cells or tumor cell equivalents. The method of claim 13, wherein the adjuvant is selected from the group Bacille Calmette-Guerin, Q-21, and detoxified endotoxin. The method of claim 11, wherein the composition is administered prior to the n of cyclophosphamide.			
3 }	2 3 5 5 1 2	consis	a) is constitution a) is constitution 14. sting of	onjugated to a hapten, and stains from about 2×10^5 to about 2.5×10^6 tumor cells or tumor cell equivalents. The method of claim 13, wherein the adjuvant is selected from the group Bacille Calmette-Guerin, Q-21, and detoxified endotoxin. The method of claim 11, wherein the composition is administered prior to the mof cyclophosphamide.			
3 }	2 3 4 5 1 2 1 2	consis	a) is composition a) is composition b) com 14. sting of 15. histration	onjugated to a hapten, and stains from about 2×10^5 to about 2.5×10^6 tumor cells or tumor cell equivalents. The method of claim 13, wherein the adjuvant is selected from the group Bacille Calmette-Guerin, Q-21, and detoxified endotoxin. The method of claim 11, wherein the composition is administered prior to the mof cyclophosphamide.			
3 }	2 3 5 5 1 2	consis	a) is composition a) is composition b) com 14. sting of 15. histration	onjugated to a hapten, and stains from about 2×10^5 to about 2.5×10^6 tumor cells or tumor cell equivalents. The method of claim 13, wherein the adjuvant is selected from the group Bacille Calmette-Guerin, Q-21, and detoxified endotoxin. The method of claim 11, wherein the composition is administered prior to the mof cyclophosphamide.			

		17 The state of th					
	1	17. The method of claim 10, wherein the tumor cells or tumor cell extracts originate					
	2	from a tumor selected from the group consisting of melanoma, ovarian cancer, colon cancer,					
	3	breast cancer, rectal cancer, lung cancer, kidney cancer, prostate cancer, and leukemia.					
	2	18. The method of claim 10, wherein the tumor cells or tumor cell extracts are autologous.					
	Pint	19. The method of claim 10, wherein the tumor is melanoma.					
:: · · · ·	1	20. The method of claim 10, wherein the patient is a human.					
Pir.	1	21. A method for inducing an anti-tumor response in a mammalian patient					
1,17	2	suffering from a tumor, which method comprises administering to the patient:					
	3	(a) on the first day of the treatment, a composition comprising autologous tumor cells or					
	4	tumor cell extracts, which corresponds to from about 2×105 to about 2.5×106 tumor cells, free of					
# 12	5	any adjuvant;					
The Head	6	(b) four to seven days after initiation of the treatment, an immunomodulatory agent that					
). []	7	potentiates protective anti-tumor immunity or inhibits immune suppression, or both; and					
hd hA	8	(c) at least one additional composition comprising autologous tumor cells or tumor cell					
	9	extracts.					
	1	22. The method of claim 21, in which the immunomodulatory compound is					
	2	cyclophosphamide.					
	1	23. A method for inducing an anti-tumor response in a mammalian patient					
	2	suffering from a tumor, which method comprises administering to the patient:					
	3	(a) on the first day of the treatment, a composition comprising a haptenized autologous					
	4	tumor cell or tumor cell extract which corresponds to from about 2×10 ⁵ to 2.5×10 ⁶ tumor cells					
	5	free from any adjuvant:					

	1
1111	
:==	
Him Him	
ij	
7	
ij	
<u>.</u>	
IJ	

1

2

3

4

- (b) four to seven days after initiation of the treatment, cyclophosphamide; and(c) at least one week after initiation of the treatment, a composition comprising an
- adjuvant and a haptenized autologous tumor cell or tumor cell extract which corresponds to from about 2×10^5 to about 1×10^7 tumor cells.
 - 24. The method in claim 22, in which the adjuvant is *Bacille Calmette-Guerin*.

Med 3